Menu Asset Reunification – ProSearch GSK has launched a tracing programme in partnership with ProSearch with the aim of reuniting 'lost' shareholders or their estates with unclaimed cash entitlements in respect of payments made by GSK, Glaxo Wellcome or SmithKline Beecham. There are various reasons why cash entitlements may not have been claimed by shareholders. The most common reasons are: Shareholder not notifying the Registrar of a change of address; or Where a Shareholder has deceased and the beneficiaries or executors of an estate are not aware of the holding. If you would like to clarify whether you or a deceased person for whose estate you act holds shares in GSK (or held shares in Glaxo Wellcome or SmithKline Beecham), please contact our Registrar, Equiniti Limited (‘Equiniti’) for further assistance. Who is ProSearch? ProSearch Asset Solutions Limited ('ProSearch') is a subsidiary of Equiniti and specialises in the research, identification and the reuniting of unclaimed assets with their owners or next of kin. They have worked with a variety of well-known companies on similar projects. Further information is provided on their website, www.prosearchassets.com. Why is this entitlement due? Cheque(s) have been issued that may have been returned to Equiniti undelivered and/or remain uncashed. These may be in respect of dividends paid either by GSK, Glaxo Wellcome or SmithKline Beecham and may also include payments issued pursuant to corporate actions such as special dividends. GSK have instructed ProSearch to try to find and assist those shareholders or their legal representatives with the repatriation of unclaimed amounts to which they may be entitled. What should you do if you have received a claim form? ProSearch will only send a claim form to an address at which they are reasonably certain that the shareholder, or their legal representative, now resides. The claim form is designed to make the recovery of entitlements as easy as possible. To use this voluntary service, please follow the instructions provided and return the signed and dated form (along with any necessary documents) to ProSearch in the pre-paid envelope provided. Why is there a fee for using this service? In the process of operating a programme to trace lost shareholders ProSearch incurs costs including data subject analysis, mailings, identity confirmation, claim validation, and a helpline. The ProSearch service is voluntary. Should you choose to use this voluntary service there will be a fee of 12.5%, plus VAT, of the cash entitlement due. In addition, where a valid share certificate for your holding is not returned with your Claim Form, ProSearch will charge an administration fee of 12.5% of the share value recovered (plus VAT) together with a lost certificate charge of 2% (plus VAT) of the value of shares reissued. ProSearch will deduct all fees from the entitlements recovered. Alternatively, you may make your own arrangements to recover your entitlements by contacting Equiniti (see Investor Contacts page). How to contact ProSearch? You can call them on 0800 389 6480 from within the UK (+44 (0)121 415 0062 if calling from outside the UK). The lines are open from 8.30am to 5.30pm Monday to Friday (excluding UK Bank Holidays). How to get further information about unclaimed entitlements or shares? Please contact Equiniti (see Investor contacts page) for further information. Arrange Direct Dividend Payments It is possible to receive your dividend payments directly into your bank or building society account. Direct dividend payments ensure quicker and more secure dividend payments, removing the risk of losing your dividend cheques. It also saves you a trip to the bank! There are a number of ways you can register your bank details with Equiniti to set up direct payments: log in to your Shareview Portfolio at www.shareview.co.uk and enter your bank details; if the shares are in your sole name you can ring Equiniti (see Investor contacts page); or complete and return a Bank Mandate Form (PDF), available from the Shareview website. RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL